Puma Biotechnology Inc (PBYI) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Puma Biotechnology Inc   (NASDAQ: PBYI)


Puma Biotechnology Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Puma Biotechnology Inc's ROI in the second quarter of 2026?
Puma Biotechnology Inc achieved a return on average invested assets (ROI) of 20.12 % in its second quarter of 2026, this is above PBYI's average return on investment of -63.96%.
Puma Biotechnology Inc invested over the 12 months ending in its second quarter of 2026 $133 million

ROI has improved compared to 19.35% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 45 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 349, from total ROI ranking in the first quarter of 2026 at 357.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 17.26 % 15.12 % 8.17 % 3.01 % -4.67 %
Y / Y Net Income Change TTM -44.86 % -35.94 % -11.35 % 134.22 % -
Investment (TTM) in Millions 143 133 135 120 116
Return On Investment (TTM) 20.12 % 19.35 % 25.9 % 31.97 % 42.79 %
PBYI's Overall Ranking # 349 # 357 # 143 # 170 # 96
Seq. Investment Change TTM 5.38 % 4.88 % 3.85 % 2.17 % 3.45 %
Seq. Net Income Change TTM 9.57 % -21.62 % -15.87 % -23.68 % 27.28 %
Net Income (TTM) in Millions 27 24 31 37 48

PBYI Company Profile >> Back to PBYI Roi Comparisons >> See Annual PBYI Return On Investment



Return On Investment PBYI's Ranking
Within: No.
Industry # 21
Sector # 46
Overall # 349

Return On Investment Statistics
High Average Low
42.38 %
-63.96 %
-238.2 %
(Jun 30 2025)   (Dec 31 2017)







Financial Statements
Puma Biotechnology Inc's II. Quarter Investments $ 143 Millions PBYI's Balance sheet
Puma Biotechnology Inc's II. Quarter Income $ 8 Millions Quarterly PBYI's Income Statement
PBYI's Income by Division See PBYI's Income by Division


PBYI Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 130 117 122 145 117
Y / Y Investment Growth 11.19 % -4.05 % -15.5 % 23.57 % 41.55 %
Net Income in Millions 31 30 22 0 -29
Y / Y Net Income Growth 2.75 % 40.23 % 1079450 % - -
Annual Return On Investment 23.87 % 25.83 % 17.67 % 0 % -24.89 %


Annual Roi Comment
In the fiscal year 2025 ROI deteriorated to 23.87 %, despite net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PBYI's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PBYI's Competitors
Subscribers only: Roi for Puma Biotechnology Inc's Suppliers
Subscribers only: Return On Investment for PBYI's Customers

Other Ratios
PBYI's Roa PBYI's Inventory Turnover Ratio PBYI's Growth Rates PBYI's Dividend Statistics
PBYI's Profitability Ratios PBYI's Asset Turnover Ratio PBYI's Dividend Growth
PBYI's Roe PBYI's Valuation Ratios PBYI's Financial Strength Ratios PBYI's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Elite Pharmaceuticals Inc   53.81 %
Idexx Laboratories Inc  51.88 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   29.37 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %

Date modified: 2026-09-08T21:33:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.